Clinical Trial Update: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating enoblituzumab in combination with retifanlimab or tebotolimab in head and neck cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Neoplasms
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Enoblituzumab (enoblituzumab)
• Retifanlimab (retifanlimab)
• tebotolimab (tebotolimab)

Snippet

Sponsor: MacroGenics | Conditions: Head and Neck Cancer, Head and Neck Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-12-20